An open-label multi-center phase 1 safety study of BXQ-350 in children and young adults with relapsed solid tumors, including recurrent malignant brain tumors

BACKGROUND: BXQ-350 is a novel anti-neoplastic agent composed of saposin C (SapC) and phospholipid dioleoylphosphatidyl-serine sodium (DOPS) that selectively binds tumor cell phosphatidylserine (PS), inducing apoptosis. BXQ-350 has demonstrated preclinical antitumor effects in high-grade gliomas (HG...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelbaki, Mohamed S., DeWire Schottmiller, Mariko Dawn, Cripe, Timothy P., Curry, Richard C., Cruze, Charles A., Her, Leah, Demko, Suzanne, Casey, Denise, Setty, Bhuvana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798181/
https://www.ncbi.nlm.nih.gov/pubmed/36590576
http://dx.doi.org/10.1016/j.heliyon.2022.e12450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798181/
https://www.ncbi.nlm.nih.gov/pubmed/36590576
http://dx.doi.org/10.1016/j.heliyon.2022.e12450

Ejemplares similares